Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 13/20 | 0.43 |
| ▸ | AOC1 | P19801 | 11/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LOX | P28300 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MELK | Q14680 | 1/20 | 0.32 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31397851 | 1.00 | AOC3 (0.43) | AOC3AOC1LOXL2KDM4ELOX | |
| SCHEMBL23902752 | 0.84 | AOC3 (0.40) | AOC3AOC1LOXL2LOXALDH1A1 | |
| SCHEMBL31397840 | 0.79 | CHRNB2 (0.38) | AOC3AOC1LOXL2 | |
| SCHEMBL17372528 | 0.79 | AOC3 (0.56) | AOC3AOC1LOXL2LOX | |
| SCHEMBL17372104 | 0.79 | AOC3 (0.47) | AOC3AOC1LOXL2KDM4EALDH1A1 | |
| SCHEMBL28972711 | 0.78 | AOC3 (0.50) | AOC3AOC1LOXL2MELK | |
| SCHEMBL20189707 | 0.78 | KDM4E (0.42) | AOC3AOC1KDM4EALDH1A1IMPDH2 | |
| SCHEMBL29784977 | 0.78 | AOC3 (0.46) | AOC3AOC1LOXL2LOXMELK | |
| SCHEMBL17372175 | 0.78 | AOC3 (0.46) | AOC3AOC1LOXL2LOXMELK | |
| SCHEMBL26781479 | 0.78 | AOC3 (0.46) | AOC3AOC1LOXL2LOXMELK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4511376-A2 | EGFR INHIBITORS IN CANCER TREATMENT | Celyn Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2023205595-A2 | EGFR INHIBITORS IN CANCER TREATMENT | CELYN THERAPEUTICS, INC (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205595-A2 | EGFR INHIBITORS IN CANCER TREATMENT | CELYN THERAPEUTICS, INC (US) | 2023-10-26 | — | — | WO | disclosed |